Browse by Audience
A new migraine prevention, CGRP monoclonal antibodies (mAbs), is injectable on a monthly or quarterly basis. In clinical practice, some patients reported that drug effectiveness does not last until the […]
Learn More >Immune-mediated necrotizing myopathy (IMNM) is an autoimmune myopathy characterised by proximal muscle weakness, high creatine kinase (CK) values, and autoantibodies recognizing 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) or the signal recognition particle (SRP). […]
Learn More >The discovery and clinical implementation of modulators of adenosine, P2Y and P2X receptors have progressed dramatically in ∼50 years since Burnstock’s definition of purinergic signaling. Although most clinical trials of […]
Learn More >Oxytocin receptor (OTR) activation at the spinal level produces antinociception. Some data suggest that central OTR activation enhances social interaction via an increase of endocannabinoids (eCB), but we do not […]
Learn More >Atopic dermatitis (AD) is the most prevalent chronic inflammatory skin condition and significantly reduces quality of life. Tight junction (TJ), which is located directly beneath the stratum corneum, maintains skin […]
Learn More >Fibromyalgia and opioid use disorder (OUD) are highly impactful chronic illnesses with substantially overlapping psychosocial, biological, and clinical features. Little previous research has examined interactions between fibromyalgia and OUD. Limiting […]
Learn More >Lebrikizumab, a high-affinity IgG4 monoclonal antibody targeting interleukin-13, prevents the formation of the interleukin-4Rα-interleukin-13Rα1 heterodimer receptor signaling complex.
Learn More >
Topical non-steroidal anti-inflammatory drugs (NSAIDs) for management of osteoarthritis pain: A consensus recommendation.
Osteoarthritis (OA) contributes to significant medical and socio-economic burden in many populations. Its prevalence is expected to rise continuously owing to the combined effects of ageing and increase in risk […]
Learn More >